SCHEMBL378796

SCHEMBL378796

O=C(N1CCN(c2ccc(F)cc2)CC1)N1CCC(C(=O)N[C@H](c2cccc(F)c2)C2CC2)(c2ccc(F)cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
TSHR P16473 3/20 0.40
LMNA P02545 2/20 0.40
MAPK1 P28482 2/20 0.40
KDM4E B2RXH2 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 2/20 0.39
OPRL1 P41146 1/20 0.39
F2 P00734 1/20 0.39
F10 P00742 1/20 0.39
PRSS1 P07477 1/20 0.39
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
THRB P10828 1/20 0.37
TACR3 P29371 2/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13102899 0.87 AKR1C3 (0.44) AKR1C3SMN1; SMN2TSHRLMNAMAPK1
SCHEMBL7909141 0.86 KIT (0.44) AKR1C3SMN1; SMN2TSHRLMNAMAPK1
SCHEMBL378327 0.83 HSD11B1 (0.41) SMN1; SMN2TSHRMAPK1OPRL1KMT2A
SCHEMBL7912322 0.83 HSD11B1 (0.41) SMN1; SMN2TSHRMAPK1OPRL1KMT2A
SCHEMBL13092455 0.80 ALDH1A1 (0.43) SMN1; SMN2TSHRLMNAKDM4EHTT
SCHEMBL7908737 0.78 PANK3 (0.48) AKR1C3SMN1; SMN2TSHRLMNAKDM4E
SCHEMBL379204 0.78 NPSR1 (0.50) AKR1C3SMN1; SMN2TSHRMAPK1KDM4E
SCHEMBL7899677 0.77 AKR1C3 (0.47) AKR1C3SMN1; SMN2TSHRMAPK1KDM4E
SCHEMBL13102591 0.77 TACR3 (0.37) SMN1; SMN2KDM4EOPRL1KMT2AMEN1
SCHEMBL7912655 0.76 PANK3 (0.47) AKR1C3SMN1; SMN2TSHRLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
EP-2408745-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-01-25 EP disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 AKR1C3 1724/4885SMN1; SMN2 1960/4885TSHR 895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.